

## BIBLIOGRAPHY

Andersen Samplers Incorporated. Operating manual for Andersen 1 ACFM non-viable ambient particle sizing samplers. Atlanta, GA: Andersen Instruments Incorporated, 1985.

Ball DJ, Hirst PH, Newman SP, Sonet B, Streel B, Vanderbist F. Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device. *International Journal of Pharmaceutics* 2002;245(1-2):123-132.

Begat P, Price R, Harris H, Morton DAV, Staniforth JN. The Influence of force Control agents on the cohesive-adhesive balance in dry powder inhaler formulations. *KONA* 2005;23:109-121.

Beilmann B, Langguth P, Hausler H, Grass P. High-performance liquid chromatography of lactose with evaporative light scattering detection, applied to determine fine particle dose of carrier in dry powder inhalation products. *Journal of Chromatography A* 2006;1107(1-2):204-207.

Boyter AC, Carter R. How do patients use their nebuliser in the community? *Respiratory Medicine* 2005;99(11):1413-1417.

British Pharmacopoeia. Aerodynamic Assessment of Fine Particles: Her Majesty's Stationery Office, Appendix XII; 2001.

Broadhead J, Edmond Rouan SK, Rhodes CT. Dry-powder inhalers: evaluation of testing methodology and effect of inhaler design. *Pharmaceutica Acta Helvetiae* 1995;70(2):125-131

Chan H-K. Dry powder aerosol drug delivery-Opportunities for colloid and surface scientists. *Colloids and Surfaces A: Physicochemical and Engineering Aspects* 2006;284-285:50-55.

Chapman KR. Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus. *The American Journal of Medicine* 1996;100(Supplement 1):S5-S10.

Dalby RN, Tiano SL. Medical devices for the delivery of therapeutic aerosols to the lungs. *Inhalation aerosols: Physical and Biological Basis for Therapy* 1996: 451-459.

de Boer AH, Hagedoorn P, Westerman EM, Le Brun PPH, Heijerman HGM, Frijlink HW. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer<sup>®</sup>) for high powder doses. *European Journal of Pharmaceutical Sciences* 2006;28(3):171-178.

de Boer AH, Le Brun PPH, van der Woude HG, Hagedoorn P, Heijerman HGM, Frijlink HW. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. *European Journal of Pharmaceutics and Biopharmaceutics* 2002;54(1):17-24.

de Boer AH, Winter HMI, Lerk CF. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. *International Journal of Pharmaceutics* 1996;130(2):231-244.

DeHaan WH, Finlay WH. Predicting extrathoracic deposition from dry powder inhalers. *Journal of Aerosol Science* 2004;35(3):309-331.

Flament MP, Leterme P, Gayot A. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. *International Journal of Pharmaceutics* 2004;275(1-2):201-209.

Florey K. Lactose, anhydrate. In: *Analytical Profiles of Drug Substances*. New York: Academic Press, Inc; 1991:369-398.

Florey K. Salbutamol. In: *Analytical Profiles of Drug Substances*. New York: Academic Press, Inc; 1981:665-690.

Geuns ERM, Toren JS, Barends DM, Bult A. Decrease of the stage-2 deposition in the twin impinger during storage of beclomethasone dipropionate dry powder inhalers in controlled and uncontrolled humidities. *European Journal of Pharmaceutics and Biopharmaceutics* 1997;44(2):187-194.

Hickey AJ, Martonen TB, Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. *Pharmaceutica Acta Helvetiae* 1996;71(3):185-190.

Hickey AJ, Thompson DC. *Pharmaceutical inhalation aerosol technology*. New York: Marcel Dekker Inc; 1992.

Hinds WC. *Aerosol Technology: A Wiley-Interscience Publication*; 1982.

Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler<sup>®</sup>, Turbuhaler<sup>®</sup> and pMDI plus spacer in asthmatic patients. *Respiratory Medicine* 2001;95:720-727.

Holzner PM, Muller BW. Particle size determination of metered dose inhalers with inertial separation methods: Apparatus A and B (BP), Four Stage Impinger and Andersen Mark II Cascade Impactor. *International Journal of Pharmaceutics* 1995;116(1):11-18.

Howarth PH. What is the nature of asthma and where are the therapeutic targets? *Respiratory Medicine* 1997;91(Supplement 1):2-8.

Keldmann T. Second-generation respiratory combination therapy: fresh thinking brings new opportunities. *Drug delivery: taking the initiative in tough times for pharma* 2004:3-7.

Kempsford R, Handel M, Mehta R, De Silva M, Daley-Yates P. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. *Respiratory Medicine* 2005;99(Supplement 1):S11-S19.

Lawrence RN. Intelligent inhalers for systemic administration? *Drug Discovery Today* 2001;6(9):445-446.

Le Brun PPH, de Boer AH, Mannes GPM, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2: Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. *European Journal of Pharmaceutics and Biopharmaceutics* 2002;54(1):25-32.

Lee KC, Suen KO, Yianneskis M, Marriott C. Investigation of the aerodynamic characteristics of inhaler aerosols with an inhalation simulation machine. *International Journal of Pharmaceutics* 1996;130(1):103-113.

Louey MD, Razia S, Stewart PJ. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. *International Journal of Pharmaceutics* 2003;252(1-2):87-98.

Machado JJB, Coutinho JA, Macedo EA. Solid-liquid equilibrium of [alpha]-lactose in ethanol/water. *Fluid Phase Equilibria* 2000;173(1):121-134.

Malcolmson RJ, Embleton JK. Dry powder formulation for pulmonary delivery. *PSTT* 1998;1:394-398.

Mendes PJ, Pinto JF, Sousa JMM. A non-dimensional functional relationship for the fine particle fraction produced by dry powder inhalers. *Journal of Aerosol Science* 2007;38(6):612-624.

Mitchell JP, Nagel MW. Particle size analysis of aerosols from medicinal inhalers. *KONA* 2004;22:32-65.

Morisset M, Moneret-Vautrin D, Commun N, Schuller A, Kanny G. Allergy to Cow Milk Proteins Contaminating Lactose, Common Excipient of Dry Powder Inhalers for Asthma. *Journal of Allergy and Clinical Immunology* 2006;117(2, Supplement 1):S95.

Newman SP, Wilding IR. Gamma scintigraphy: an in vivo technique for assessing the equivalence of inhaled products. *International Journal of Pharmaceutics* 1998;170(1):1-9.

Pang Y, Sakagami M, Byron PR. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition. *European Journal of Pharmaceutical Sciences* 2005;25(4-5):369-378.

Prime D, Atkins PJ., Slater A, et al. Review of dry powder inhalers. *Advanced Drug Delivery Reviews* 1997;26:51-58.

Richter K. Successful use of DPI systems in asthmatic patients key parameters. *Respiratory Medicine* 2004;98(Supplement 2):S22-S27.

Rubin BK. Other medications for aerosol delivery. *Paediatric Respiratory Reviews* 2006;7(Supplement 1):S76-S79.

Saint-Lorant G, Leterme P, Gayot A, Flament MP. Influence of carrier on the performance of dry powder inhalers. *International Journal of Pharmaceutics* 2007;334(1-2):85-91.

Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. *Pulmonary Pharmacology & Therapeutics* 2003;16(2):79-95.

Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications : Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. *Respiratory Medicine* 1999;93(2):123-133.

Srichana T, Martin GP, Marriott C. Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro. *European Journal of Pharmaceutical Sciences* 1998;7:73-80.

Srichana T, Suedee R, Reanmongkol W. Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. *Respiratory Medicine* 2001;95:513-519.

Srichana T, Suedee R, Srisudjai P. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. *Pharmazie* 2003;58:125-129.

Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. *International Journal of Pharmaceutics* 2004;270(1-2):297-306.

Surender K, Peter SC. Metered dose inhaler: past, present, and future. *Annual Allergy Asthma Immunology* 1998;80:11-21.

Taylor K. Pulmonary drug delivery. In: Aulton ME, ed. *Pharmaceutics: Science of Dosage Form Design*. New York: Churchill Livingstone; 2002:473-488.

Thoren P, Wallin A, Whitehead PJ, Sandstrom T. The effect of different concentrations of lactose powder on the airway function of adult asthmatics. *Respiratory Medicine* 2001;95(11):870-875.

United States Pharmacopeia 25. first annual asian ed. Rockville, MD: US Pharmacopeial Convention, Inc.; 2002.

Van Der Palen J. Peak inspiratory flow through Diskus and Turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL<sup>®</sup>). *Respiratory Medicine* 2003;97(3):285-289.

Vaughan NP. The Andersen cascade impactor: calibration, wall losses and numerical simulation. *Journal of Aerosol Sciences* 1989;20:67-90.

Voss A, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. *International Journal of Pharmaceutics* 2002;248(1-2):39-50.

Whelan J. Electronic DPI for insulin. *Drug Discovery Today* 2002;7(4):213-214.

Young PM, Edge S, Traini D, et al. The influence of dose on the performance of dry powder inhalation systems. *International Journal of Pharmaceutics* 2005; 296(1-2): 26-33.